Premium
Androgen receptor action in hormone‐dependent and recurrent prostate cancer
Author(s) -
Agoulnik Irina U.,
Weigel Nancy L.
Publication year - 2006
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.20811
Subject(s) - prostate cancer , androgen receptor , androgen , cancer research , medicine , prostate , prostate specific antigen , receptor , cancer , hormone , endocrinology , oncology
The importance of androgens and androgen receptors (AR) in primary prostate cancer is well established. Metastatic disease is usually treated with some form of androgen ablation, which is effective for a limited amount of time. The role of AR in prostate cancers that recur despite androgen ablation therapy is less certain. Most of these tumors express prostate specific antigen (PSA), an androgen‐regulated gene; moreover, AR is generally highly expressed in recurrent prostate cancer. We propose that AR continues to play a role in many of these tumors and that it is not only the levels of AR, ligands, and co‐regulators, but also the changes in cell signaling that induce AR action in recurrent prostate cancer. These pathways are, therefore, potential therapeutic targets. J. Cell. Biochem. 99: 362–372, 2006. © 2006 Wiley‐Liss, Inc.